Filter Results:
(1,173)
Show Results For
- All HBS Web
(1,173)
- People (4)
- News (312)
- Research (667)
- Multimedia (16)
- Faculty Publications (357)
Show Results For
- All HBS Web
(1,173)
- People (4)
- News (312)
- Research (667)
- Multimedia (16)
- Faculty Publications (357)
- February 2019 (Revised August 2019)
- Case
Maccabitech: The Promise of Israel's Healthcare Data
By: Scott Duke Kominers and Carin-Isabel Knoop
Dr. Varda Shalev bridges technology and medicine through Maccabitech, a "research and innovation wing" of Israel's Maccabi Healthcare Services (MHS) that partners with research institutions, pharmaceutical companies, and startups. Shalev hopes to scale Maccabitech's... View Details
Keywords: Big Data; Healthcare; Analytics and Data Science; Digital Platforms; Health Care and Treatment; Innovation and Invention; Research; Entrepreneurship; Risk Management; Israel
Kominers, Scott Duke, and Carin-Isabel Knoop. "Maccabitech: The Promise of Israel's Healthcare Data." Harvard Business School Case 819-032, February 2019. (Revised August 2019.)
- Web
HBS - From The Dean
community. It was also a year when we made significant progress on several important priorities. At a moment when AI took center stage with the advent of ChatGPT, our own digital transformation—exploring how we can leverage data and... View Details
- 2024
- Working Paper
Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the... View Details
Keywords: Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms
Bhidé, Amar, and Srikant M. Datar. "Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 21-035, August 2020. (Revised May 2024.)
- 07 Sep 2021
- News
One Degree of Difference
Courtesy Paris Wallace Courtesy Paris Wallace At 70 employees strong, the Boston-based digital company Ovia Health is on the smallish-but-mighty size compared to the rest of the local tech hub. Competing for... View Details
- Article
Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate." Pharmacy in History 45, no. 1 (2003): 3–17.
Carlos Reines
telecom companies in the world. He began his career in digital health at Siemens Medical in Pennsylvania. He obtained his Engineering degree at the Polytechnic University in Madrid, Spain; with... View Details
- December 2024
- Article
Is There Too Little Antitrust Enforcement in the U.S. Hospital Sector?
By: Zarek Brot-Goldberg, Zack Cooper, Stuart Craig and Lev Klarnet
From 2002 to 2020, there were over 1,000 mergers of U.S. hospitals. During this period, the Federal Trade Commission (FTC) took enforcement actions against 13 transactions. However, using the FTC’s standard screening tools, we find that 20% of these mergers could have... View Details
Keywords: Monopoly; Mergers and Acquisitions; Governing Rules, Regulations, and Reforms; Competition; Health Industry
Brot-Goldberg, Zarek, Zack Cooper, Stuart Craig, and Lev Klarnet. "Is There Too Little Antitrust Enforcement in the U.S. Hospital Sector?" American Economic Review: Insights 6, no. 4 (December 2024): 526–542.
- 03 Dec 2015
- Op-Ed
How "New Nuclear" Power Could Save the Planet—If Regulators Would Allow It
Leaders from some 150 nations have convened in Paris this week for the COP21 conference with a singular goal: to fight the global threat of climate change. Each of them have brought to Paris their own national plan for reducing greenhouse gas emissions that drive... View Details
- 11 May 2010
- First Look
First Look: May 11
understood, even as the United States, Germany, and the United Kingdom instituted reforms in early 2010. Presenting opportunities for cross-national policy learning, this case describes the political economy of healthcare reform. In late... View Details
Keywords: Martha Lagace
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 19 Dec 2016
- Blog Post
The Making of An Internship: Impact
influence an organizations’ success longterm. Watch as three Class of 2017 students highlight the projects they worked on during their summer internships, and the impacts they made. Francesca Ioffreda created the business case for a new View Details
Keywords: All Industries
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Geographic Location; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Demand and Consumers; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- 10 Jul 2018
- First Look
New Research and Ideas, July 10, 2018
Bangladesh, Africa, and Chile, benefiting the public as well as their own enterprises. He then describes how an Indian health care organization is tackling institutional voids as it expands into medical tourism in the Cayman Islands. An... View Details
Keywords: Dina Gerdeman
- 15 Oct 2019
- News
Engaging More Deeply with Business in Africa
understand business in Africa. In November, the ARC expanded its coverage on the continent with the hiring of Wale Lawal, a senior researcher who will be based in Lagos. Professor Tsedal Neeley spoke about the global digital leader during... View Details
- 2009
- Working Paper
Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
By: Arthur Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Health Testing and Trials; Power and Influence; Competitive Strategy; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur. "Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location." Harvard Business School Working Paper, No. 09-118, April 2009.
- Web
Preface - Coin and Conscience – Baker Library | Bloomberg Center, Historical Collections
added benefit of digital access to all seventy items described in the catalog. The text below, the citations in the gallery, the artist index, and the bibliography are reproduced here from the 1986 publication. The exhibition catalog is... View Details
- August 2008 (Revised May 2009)
- Background Note
Note on Generic Drugs in the European Union
By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
- August 2001
- Case
Scios, Inc.
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
- 15 Dec 2024
- News
On The Case
Professor Linda Hill first met Tom Mihaljevic (GMP 15, 2013) when he came to campus to participate in a fireside chat that Hill unexpectedly wound up facilitating. At that time, he was the CEO of Cleveland Clinic Abu Dhabi, and the pair found they had a lot to talk... View Details
- 25 Aug 2022
- News
Ready for Departure
news? Probably another blip. Changi also implemented a host of new health and safety measures to make the various touch points throughout the airport less touchy. Changi also implemented a host of new health... View Details